Neurological Disorder Diagnostics Market Report 2026

The neurological disorder diagnostics market size has grown strongly in recent years. It will grow from $12.61 billion in 2025 to $13.54 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, rising awareness of early diagnosis importance, expansion of advanced imaging infrastructure, growing research funding for neurology, improved availability of diagnostic instruments.

The neurological disorder diagnostics market size is expected to see strong growth in the next few years. It will grow to $17.75 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing adoption of precision neurology approaches, rising investments in digital diagnostics platforms, expansion of personalized treatment planning, growing use of tele-neurology services, advancements in neuroinformatics and analytics. Major trends in the forecast period include increasing adoption of AI-assisted neuroimaging tools, rising use of biomarker-based diagnostic kits, growing integration of genetic and molecular testing, expansion of remote and digital cognitive assessments, enhanced focus on early disease detection.

The rising prevalence of Alzheimer’s disease is anticipated to drive the growth of the neurological disorder diagnostics market in the coming years. Alzheimer’s disease is a progressive neurodegenerative condition marked by a gradual deterioration in cognitive abilities, including memory, reasoning, and problem-solving skills. The disease arises from a combination of genetic factors, such as specific gene mutations and variations, along with the buildup of amyloid plaques and tau tangles in the brain, chronic inflammation, vascular complications, and lifestyle-related influences. Neurological disorder diagnostics support the management of Alzheimer’s disease by facilitating early and precise identification through advanced imaging technologies, biomarker analyses, and cognitive evaluation tools. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023 approximately 411,100 people in Australia were living with dementia, including about 257,500 women and 153,700 men. Therefore, the increasing prevalence of Alzheimer’s disease is contributing to the expansion of the neurological disorder diagnostics market.

Major companies operating in the neurological disorder diagnostics market are concentrating on developing advanced solutions, such as neurological disease quantification software, to address the needs of the nearly one billion people affected by neurological conditions worldwide. Neurological disease quantification software refers to tools designed to assess and evaluate brain function and track disease progression in individuals with neurological disorders. For example, in January 2024, Quibim, a Spain-based biotechnology company, introduced QP-Brain, an AI-driven software for early-stage neurological disease quantification. QP-Brain is a sophisticated neuroimaging analysis solution that enables the measurement of brain tissue changes associated with neurological diseases. Its distinguishing capabilities include AI-enabled automated segmentation and comprehensive volumetric analysis, delivering accurate insights into structural brain alterations for both clinical and research use.

In February 2023, Lantheus, a US-based pharmaceutical manufacturing company, acquired Cerveau Technologies for an undisclosed sum. Through this acquisition, along with Cerveau’s tau-targeting PET imaging agent MK-6240, Lantheus significantly strengthens its capacity to diagnose, stage, and monitor Alzheimer’s disease while also advancing the development of novel therapeutic approaches. Cerveau Technologies is a US-based company that focuses on the development of diagnostic technologies for neurological disorders, with a primary emphasis on neurodegenerative diseases such as Alzheimer’s.

Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation.

North America was the largest region in the neurological disorder diagnostics market in 2025. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurological disorder diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neurological disorder diagnostics market by increasing costs of imported imaging systems, laboratory reagents, diagnostic kits, genetic testing consumables, and advanced software solutions. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported MRI, CT, and PET equipment, while Asia-Pacific faces higher costs for reagents and testing kits. These tariffs are increasing diagnostic procedure costs and slowing technology upgrades. However, they are also encouraging local manufacturing of diagnostic consumables, regional software development, and domestic production of imaging accessories, supporting long-term market resilience.

The neurological disorder diagnostics market research report is one of a series of new reports that provides neurological disorder diagnostics market statistics, including neurological disorder diagnostics industry global market size, regional shares, competitors with a neurological disorder diagnostics market share, detailed neurological disorder diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder diagnostics industry. This neurological disorder diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurological disorder diagnostics encompass the range of methods and technologies employed to identify, evaluate, and monitor conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. These diagnostics utilize advanced imaging techniques, biomarker analysis, genetic testing, and cognitive evaluations to detect abnormalities, establish the presence and progression of diseases, and inform treatment approaches for neurological disorders.

Key components in the neurological disorder diagnostics market include instruments, reagents, kits, software, and services. Instruments refer to the physical tools used in diagnosing neurological conditions. The technologies employed include immunoassay and polymerase chain reaction (PCR) methods, targeting a variety of diseases such as Alzheimer’s disease, dementia, Parkinson’s disease, epilepsy, traumatic brain injury, and others. The end users comprise hospitals and clinics, diagnostic laboratories, and academic and research institutions.

The neurological disorder diagnostics market consists of revenues earned by entities by providing services such as neuroimaging, electrophysiological testing, genetic analysis, cerebrospinal fluid examination, neuropsychological assessments, and laboratory tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurological disorder diagnostics market also includes sales of imaging devices, biomarker tests, and cognitive assessment tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.